References
1. Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and
Treatment of Psoriasis: A Review. Jama . May 19
2020;323(19):1945-1960.
2. Griffiths CE, Christophers E, Barker JN, et al. A classification of
psoriasis vulgaris according to phenotype. Br J Dermatol . Feb
2007;156(2):258-262.
3. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis.Lancet . Apr 3 2021;397(10281):1301-1315.
4. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of
care for the management and treatment of psoriasis with biologics.J Am Acad Dermatol . Apr 2019;80(4):1029-1072.
5. Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of
care for the management and treatment of psoriasis with topical therapy
and alternative medicine modalities for psoriasis severity measures.J Am Acad Dermatol . Feb 2021;84(2):432-470.
6. Hendriks AG, Keijsers RR, de Jong EM, Seyger MM, van de Kerkhof PC.
Efficacy and safety of combinations of first-line topical treatments in
chronic plaque psoriasis: a systematic literature review. J Eur
Acad Dermatol Venereol . Aug 2013;27(8):931-951.
7. Mason A, Mason J, Cork M, Hancock H, Dooley G. Topical treatments for
chronic plaque psoriasis: an abridged Cochrane systematic review.J Am Acad Dermatol . Nov 2013;69(5):799-807.
8. Mason AR, Mason J, Cork M, Dooley G, Hancock H. Topical treatments
for chronic plaque psoriasis. Cochrane Database Syst Rev . Mar 28
2013;(3):Cd005028.
9. Schlager JG, Rosumeck S, Werner RN, et al. Topical treatments for
scalp psoriasis: summary of a Cochrane Systematic Review. Br J
Dermatol . Mar 2017;176(3):604-614.
10. Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH. Topical
therapies for the treatment of plaque psoriasis: systematic review and
network meta-analyses. Br J Dermatol . May 2013;168(5):954-967.
11. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension
statement for reporting of systematic reviews incorporating network
meta-analyses of health care interventions: checklist and explanations.Ann Intern Med . Jun 2 2015;162(11):777-784.
12. Kelley GA, Kelley KS. Statistical models for meta-analysis: A brief
tutorial. World J Methodol . Aug 26 2012;2(4):27-32.
13. Thom H, White IR, Welton NJ, Lu G. Automated methods to test
connectedness and quantify indirectness of evidence in network
meta-analysis. Res Synth Methods . Mar 2019;10(1):113-124.
14. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in
mixed treatment comparison meta-analysis. Stat Med . Mar 30
2010;29(7-8):932-944.
15. Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR.
Consistency and inconsistency in network meta-analysis: concepts and
models for multi-arm studies. Res Synth Methods . Jun
2012;3(2):98-110.
16. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G.
Graphical tools for network meta-analysis in STATA. PLoS One .
2013;8(10):e76654.
17. Mbuagbaw L, Rochwerg B, Jaeschke R, et al. Approaches to
interpreting and choosing the best treatments in network meta-analyses.Syst Rev . Apr 12 2017;6(1):79.
18. Papp KA, Bissonnette R, Gooderham M, et al. Treatment of plaque
psoriasis with an ointment formulation of the Janus kinase inhibitor,
tofacitinib: a Phase 2b randomized clinical trial. BMC Dermatol .
Oct 3 2016;16(1):15.
19. Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 Trials of
Tapinarof Cream for Plaque Psoriasis. N Engl J Med . Dec 9
2021;385(24):2219-2229.
20. Robbins K, Bissonnette R, Maeda-Chubachi T, et al. Phase 2,
randomized dose-finding study of tapinarof (GSK2894512 cream) for the
treatment of plaque psoriasis. J Am Acad Dermatol . Mar
2019;80(3):714-721.
21. Cai L, Chen GH, Lu QJ, et al. A double-blind, randomized, placebo-
and positive-controlled phase III trial of 1% benvitimod cream in
mild-to-moderate plaque psoriasis. Chin Med J (Engl) . Nov 9
2020;133(24):2905-2909.
22. Bissonnette R, Bolduc C, Maari C, et al. Efficacy and safety of
topical WBI-1001 in patients with mild to moderate psoriasis: results
from a randomized double-blind placebo-controlled, phase II trial.J Eur Acad Dermatol Venereol . Dec 2012;26(12):1516-1521.
23. Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of Roflumilast Cream
for Chronic Plaque Psoriasis. N Engl J Med . Jul 16
2020;383(3):229-239.
24. Pinter A, Green LJ, Selmer J, Praestegaard M, Gold LS, Augustin M. A
pooled analysis of randomized, controlled, phase 3 trials investigating
the efficacy and safety of a novel, fixed dose calcipotriene and
betamethasone dipropionate cream for the topical treatment of plaque
psoriasis. J Eur Acad Dermatol Venereol . Feb 2022;36(2):228-236.
25. Koo J, Tyring S, Werschler WP, et al. Superior efficacy of
calcipotriene and betamethasone dipropionate aerosol foam versus
ointment in patients with psoriasis vulgaris–A randomized phase II
study. J Dermatolog Treat . 2016;27(2):120-127.
26. Leonardi C, Bagel J, Yamauchi P, et al. Efficacy and Safety of
Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients
With Psoriasis Vulgaris–a Randomized Phase III Study (PSO-FAST).J Drugs Dermatol . Dec 2015;14(12):1468-1477.
27. Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus
betamethasone dipropionate aerosol foam provides superior efficacy vs.
gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE
study. J Eur Acad Dermatol Venereol . Jan 2017;31(1):119-126.
28. Gold LS, Lebwohl MG, Sugarman JL, et al. Safety and efficacy of a
fixed combination of halobetasol and tazarotene in the treatment of
moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized
controlled trials. J Am Acad Dermatol . Aug 2018;79(2):287-293.
29. Lebwohl M, Kircik LH, Moore A, Gold LS, Del Rosso J, Draelos ZD, et
al. Once-daily roflumilast cream 0.3%, a potent phosphodiesterase-4
inhibitor, provided safe and effective treatment of psoriasis in the
DERMIS-1 and DERMIS-2 phase 3 trials [abstract 2063]. EADV 30th
Congress; 2021.
30. Langley RG, Gupta A, Papp K, Wexler D, Østerdal ML, Curčić D.
Calcipotriol plus betamethasone dipropionate gel compared with
tacalcitol ointment and the gel vehicle alone in patients with psoriasis
vulgaris: a randomized, controlled clinical trial. Dermatology .
31. Sugarman JL, Gold LS, Lebwohl MG, Pariser DM, Alexander BJ, Pillai
R. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled
Clinical Study to Assess the Safety and Efficacy of a
Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque
Psoriasis. J Drugs Dermatol . Mar 1 2017;16(3):197-204.
32. Lebwohl M, Tyring S, Bukhalo M, et al. Fixed Combination Aerosol
Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064%
(BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis
Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2
Study. J Clin Aesthet Dermatol . Feb 2016;9(2):34-41.
33. Menter A, Gold LS, Bukhalo M, et al. Calcipotriene plus
betamethasone dipropionate topical suspension for the treatment of mild
to moderate psoriasis vulgaris on the body: a randomized, double-blind,
vehicle-controlled trial. J Drugs Dermatol . Jan 2013;12(1):92-98.
34. Feldman SR, Matheson R, Bruce S, et al. Efficacy and safety of
calcipotriene 0.005% foam for the treatment of plaque-type psoriasis:
results of two multicenter, randomized, double-blind,
vehicle-controlled, phase III clinical trials. Am J Clin
Dermatol . Aug 1 2012;13(4):261-271.
35. Green LJ, Kerdel FA, Cook-Bolden FE, et al. Safety and Efficacy of a
Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of
Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized
Controlled Trials. J Drugs Dermatol . Oct 1 2018;17(10):1062-1069.
36. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane
Collaboration’s tool for assessing risk of bias in randomised trials.Bmj . Oct 18 2011;343:d5928.
37. Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient:
Psoriasis comorbidities and preferred systemic agents. J Am Acad
Dermatol . Jan 2019;80(1):27-40.
38. Puig L, Carrascosa JM, Belinchón I, et al. Adherence and patient
satisfaction with topical treatment in psoriasis, and the use, and
organoleptic properties of such treatments: a Delphi study with an
expert panel and members of the Psoriasis Group of the Spanish Academy
of Dermatology and Venereology. Actas Dermosifiliogr . Jul-Aug
2013;104(6):488-496.
39. Stein Gold LF. Topical Therapies for Psoriasis: Improving Management
Strategies and Patient Adherence. Semin Cutan Med Surg . Mar
2016;35(2 Suppl 2):S36-44; quiz S45.
40. Kragballe K, van de Kerkhof P. Pooled safety analysis of
calcipotriol plus betamethasone dipropionate gel for the treatment of
psoriasis on the body and scalp. J Eur Acad Dermatol Venereol .
May 2014;28 Suppl 2:10-21.
41. Lé AM, Torres T. New Topical Therapies for Psoriasis. Am J
Clin Dermatol . Jan 2022;23(1):13-24.
42. Bissonnette R, Iversen L, Sofen H, et al. Tofacitinib withdrawal and
retreatment in moderate-to-severe chronic plaque psoriasis: a randomized
controlled trial. Br J Dermatol . 2015;172(5):1395-1406.
43. Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and
safety trial of the topical Janus kinase inhibitor tofacitinib in the
treatment of chronic plaque psoriasis. Br J Dermatol . Jul
2013;169(1):137-145.
44. Hosking AM, Juhasz M, Mesinkovska NA. Topical Janus kinase
inhibitors: A review of applications in dermatology. J Am Acad
Dermatol . Sep 2018;79(3):535-544.
45. Nogueira M, Puig L, Torres T. JAK Inhibitors for Treatment of
Psoriasis: Focus on Selective TYK2 Inhibitors. Drugs . Mar
2020;80(4):341-352.
46. Takahashi H, Katayama H, Uwajima Y, et al. Patient satisfaction and
efficacy of calcipotriol plus betamethasone dipropionate gel in plaque
psoriasis patients with poor adherence. J Dermatol . Nov
2020;47(11):1249-1256.